Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. The company's lead clinical candidate is the VY-AADC01, which is in Phase Ib clinical trial for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-FXN01 for Friedreich's ataxia; VY-HTT01 for Huntington's disease; and VY-SMN101 for spinal muscular atrophy. The company has strategic collaboration agreements with Genzyme Corporation and the University of Massachusetts. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
http://www.priceseries.com/trade/VYGR-Voyager-Therapeutics-Inc-stock-gains-140-percent-a-Trade-Record-by-priceSeries-2017082520171013.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments